Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy
- 25 October 2022
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 19 (3) , 347-354
Abstract
Purpose: To evaluate the prognostic value of human epidermal growth factor receptor 2 (HER2) status and how to use HER2‐targeted therapy in breast cancer (BC) with brain metastases (BM) treated with radiotherapy.Methods: We retrospectively reviewed the data of 103 BC patients with parenchymal BM treated with radiotherapy. We collected data on the hormone receptor (HR), HER‐2 amplification status, and systemic therapy after treatment for BM. The primary outcome was overall survival (OS), which was calculated from the diagnosis of BM to death.Results: The median follow‐up time from the diagnosis of the first BM was 9.1 months (range, .7–88 months). The 2‐year OS of the HR‐positive and HER2‐positive (HR+HER2+) BC (31.3 mo) was significantly better than those of the HR‐HER2+ (9,5 mo, p=.002), HR+HER2‐ (9.9mo, p=.003), and triple‐negative BC (3.9 mo, p<.001) ( . Of the 36 HER2‐positive patients, 31 patients treated with HER2‐targeted therapy after radiotherapy for BM had a significantly better 2‐year OS than those who did not receive HER2‐targeted therapy (43% vs. 0%; p < .001). Among the 31 patients treated with HER2‐targeted therapy, the 2‐year OS for those treated with multiple anti‐HER2 agents during the entire course of treatment was significantly higher than that for patients treated with a single agent (60% vs. 24%; p = .006).Conclusions: HR+HER2+ BC patients with BM treated with radiotherapy show a better prognosis than other subtypes. For HER2‐positive patients with good prognosis, it may be important to continue HER2‐targeted therapy appropriately after radiotherapy for BM.Keywords
This publication has 27 references indexed in Scilit:
- Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood–brain barrierCancer Treatment Reviews, 2013
- Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab erasRadiation Oncology, 2013
- Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survivalBritish Journal of Cancer, 2012
- Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancerBMC Cancer, 2010
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Trastuzumab treatment in patients with breast cancer and metastatic CNS diseaseAnnals of Oncology, 2009
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrierAnti-Cancer Drugs, 2007
- Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast CancerJournal of Clinical Oncology, 2006
- Survival After Brain Metastases From Breast Cancer in the Trastuzumab EraJournal of Clinical Oncology, 2005